RecruitingNCT04904146

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

Sponsor

Lund University Hospital

Enrollment

120 participants

Start Date

Apr 2, 2021

Study Type

OBSERVATIONAL

Conditions

Mycosis Fungoides Sezary Syndrome

Summary

A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood, tissue, and other samples from people with mycosis fungoides or Sézary syndrome (two types of lymphoma that mainly affect the skin) to find biological markers that can predict how the disease will behave and how it will respond to treatment. **You may be eligible if...** - You are between 18 and 100 years old - You have been diagnosed with mycosis fungoides or Sézary syndrome (any stage, I through IV) confirmed by biopsy - You are in reasonable general health - You have no psychiatric condition that would prevent participation - You have provided written informed consent **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBlood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.

The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.